ADRB2 and neoplasm: Although IHC detection of the β-AR receptors is not necessarily indicative of the level of tumor responsiveness to β-blockade, it does help identify β-AR positive cancers that may benefit from this emerging treatment, while excluding cancers from future studies that do not express these receptors.